Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.inf.0000164799.33635.fe | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pharmacoeconomic Study of Post-Exposure Prophylaxis Strategies for Influenza Virus Infections in Japan.
Adv Ther
December 2024
School of Pharmaceutical Sciences, Ohu University, 31-1 Misumido, Tomita-machi, Koriyama, Fukushima, 963-8611, Japan.
Introduction: Vaccines can prevent influenza (flu) infections and are cost-effective for society and healthcare. However, the cost-effectiveness of post-exposure prophylaxis as a follow-up strategy is unclear. This study aims to evaluate the cost utility of post-exposure prophylaxis and treatment strategies with neuraminidase inhibitors and a cap-dependent endonuclease inhibitor for flu infections from the perspective of healthcare costs in Japan.
View Article and Find Full Text PDFZanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant.
Int J Antimicrob Agents
September 2024
Virology Department, AP-HP, Hôpital Saint Louis, Paris, France; Université Paris Cité, Inserm U976, Insight team, Paris, France. Electronic address:
Objectives: Immunocompromised patients may experience prolonged shedding of influenza virus potentially leading to severe infections. Alternatives to monotherapy with neuraminidase inhibitors should be evaluated to entirely suppress viral replication and prevent drug-resistant mutations.
Methods: We investigated the clinical and virological evolution in a case of persistent influenza A and human coronavirus OC43 (HCoV-OC43) coinfection in a hematopoietic stem cell transplant recipient after different therapeutic strategies.
Receptor-Based Pharmacophore Modelling of a series of ligands used as inhibitors of the SARS-CoV-2 virus by complementary theoretical approaches, molecular docking, and reactivity descriptors.
F1000Res
September 2024
Departamento de Química-Física, Universidad de Cadiz, Cádiz, Andalusia, Spain.
A identified in 2019, - - , has a pandemic of respiratory , called - Most people with COVID-19 experience mild to moderate symptoms and recover without the need for special treatments. The SARS‑CoV‑2 RNA‑dependent RNA polymerase (RdRp) plays a crucial role in the viral life cycle. The active site of the RdRp is a very accessible region, so targeting this region to study the inhibition of viral replication may be an effective therapeutic approach.
View Article and Find Full Text PDFChanging Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022.
Clin Infect Dis
August 2023
Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Introduction: Understanding the changing epidemiology of adults hospitalized with coronavirus disease 2019 (COVID-19) informs research priorities and public health policies.
Methods: Among adults (≥18 years) hospitalized with laboratory-confirmed, acute COVID-19 between 11 March 2021, and 31 August 2022 at 21 hospitals in 18 states, those hospitalized during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-predominant period (BA.1, BA.
Lung ultrasound-guided treatment for acute respiratory distress syndrome in a critically ill patient with severe COVID-19: a case report.
Ann Palliat Med
December 2022
Department of Intensive Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Background: Acute respiratory distress syndrome (ARDS) is a very common disease in the intensive care unit (ICU), with rapid progression and high mortality. Infections caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can easily progress to ARDS in severely ill patients. Early and rapid diagnosis as well as screening for ARDS during treatment is very important.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!